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A B S T R A C T   
Introduction and importance: Hajdu Cheney Syndrome (HCS) is a rare skeletal disease characterized by severe, 
progressive focal bone loss with osteoporosis, variable craniofacial, vertebral anomalies and distinctive facial 
features. It is inherited as an autosomal dominant disease although sporadic cases have been described in 
literature. Identifying these cases in clinical practice is important for proper diagnosis and management. 
Case presentation: We report a case of a 36-year-old male patient presented at metabolic bone disease clinic at the 
Aga Khan University Hospital with history of multiple fragility fractures and juvenile osteoporosis since child-
hood. DNA sequence analysis of the NOTCH2 coding sequence revealed a pathogenic variant in NOTCH 2, Exon 
34, c.6426_6427insTT (p.Glu2143Leufs*5), consistent with a NOTCH2 related conditions including HCS. 
Clinical discussion: The multitude of presentations associated with HCS are linked to the NOTCH2 gene, as Notch 
signaling is one of the core signaling pathways that control embryonic development. Hence, mutations in the 
Notch signaling pathway cause developmental phenotypes that affect various organs including the liver, skel-
eton, heart, eye, face, kidney, and vasculature. 
Conclusion: To the best of our knowledge, nucleotide mutations of c.6933delT, c.6854delA, c.6787C.T, and 
c.6424-6427delTCTG were all determined to be novel, with c.6428T > C being the most common mutation found 
in literature. The c.6426_6427insTT mutation our patient was found to have via gene sequencing too appears to 
be a novel mutation, which has not previously been reported in literature.   
1. Introduction 
Hajdu Cheney Syndrome (HCS) is a rare skeletal disease character-
ized by severe, progressive focal bone loss with osteoporosis, variable 
craniofacial, vertebral anomalies and distinctive facial features. It is 
inherited as an autosomal dominant disease although sporadic cases 
have been described in literature [1]. There is marked phenotypic 
variability and the degree of severity in clinical features between 
affected individuals and hence it often remains undiagnosed until 
adolescence or adulthood [2]. Thus, despite the fact that the disease 
begins to manifest at birth, it is still extremely rare with fewer than one 
hundred cases found in the literature [3]. 
The disease was linked to mutations in the Notch Receptor 2 
(NOTCH2) gene in 2011 by whole-exome sequencing in individuals with 
HCS. Specifically, mutations of exon 34 have been shown to remove 
PEST domains, a peptide sequence that is rich in proline (P), glutamic 
acid (E), serine (S), and threonine (T) due to a premature stop in amino 
acid codon, creating a truncated and stable NOTCH2 protein with 
enhanced NOTCH2 signaling activity [1,4–6]. Dysregulation of Notch 
signaling is associated with skeletal developmental disorders and bone 
remodeling, and gain-of-function mutations of NOTCH2 are associated 
with HCS [3]. Notch receptors are single-pass trans membrane proteins 
that determine cell fate and play a critical role in skeletal development 
and homeostasis [3]. Furthermore, NOTCH2 is present in all embryonic 
tissue and hence manifested as wide phenotype with a variety of clinical 
manifestations, related to skeletal development & homeostasis [1]. 
Identifying these cases in clinical practice is important for proper 
diagnosis and management. The unknown mechanism of disease 
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progression and bone loss amongst affected individuals poses a unique 
therapeutic challenge. Continued research is critically important to 
build on prior knowledge so that advancement related to drug devel-
opment and treatment in the rare diseases of bone to improve bone 
health can be made. 
We present the first case diagnosed with HCS from our metabolic 
bone disease clinic at Aga Khan University Hospital, Karachi, Pakistan. 
We also performed a review of the literature to understand the pheno-
typic and genotypic spectrum of the disease, and treatment regimens 
utilized for its management. We searched the MEDLINE database for 
studies with the search terms “NOTCH2” and “Hajdu Cheney Syndrome” 
from 2012 to 2019 with English language restrictions. The title, abstract 
and full text of all documents identified according to these search 
criteria were scrutinized by the authors. Additionally, all references 
found in the published articles were also reviewed for case report 
ascertainment. This is an attempt to analyze the complete phenotype of 
HCS for better understanding of the syndrome and contribute to an 
earlier diagnosis in new cases. Further, it is also important for genetic 
counselling. Written informed consent was obtained from the patient for 
publication of this case report. This work has been reported in line with 
the Case Report (CARE) guidelines [7,8]. 
2. Case report 
A 36-year-old male patient presented at metabolic bone disease 
clinic at the Aga Khan University Hospital with history of multiple 
fragility fractures and juvenile osteoporosis since childhood. There was 
no history of neurological or cardiovascular complications nor any uri-
nary symptoms. 
Upon physical examination, the patient’s height was 159 cm and 
weight was 95 kg. He displayed a prominent forehead, hypertelorism, 
long eyelashes, and micrognathia. Furthermore, his hands were short 
and stubby with acroosteolysis and broad dark nails. There were no signs 
of local inflammation in either fingers or toes. He had lost all his teeth 
and had replaced them with dentures. The liver and spleen were not 
palpable and no abnormalities were noted on cardiovascular and 
neurological exams. Previous consultations in the United States of 
America, during his childhood had considered the possibility of HCS due 
to the presence of acroosteolysis. He had been taking bisphosphonates 
including Pamidronate and Zoledronic Acid since childhood. He was on 
Prolia when he presented this time. 
Table 1 shows the results of bone biochemistry and Dual-energy X- 
ray absorptiometry (DXA) findings at an interval of two years. Complete 
blood count, serum electrolytes, liver and renal function tests (except 
gamma-GT, which was marginally raised) were within the normal range 
on different occasions. In addition, thyroid profile, follicle stimulating 
hormone, and luteinizing hormone & free androgen index were also 
within the reference intervals. 
Based on history & facial dysmorphism, he was referred for geneticist 
consult. DNA sequence analysis of the NOTCH2 coding sequence was 
performed on genomic DNA extracted from peripheral leucocytes at the 
Invitae Corporation, San Francisco CA 94103. A pathogenic variant in 
NOTCH2, Exon 34, c.6426_6427insTT (p.Glu2143Leufs*5) heterozy-
gous was identified, consistent with a predisposition to, or diagnosis of 
NOTCH2 related conditions including HCS (MedGen UID: 182961) and 
Alagille syndrome 2 (ALGS2) (MedGen UID: 341844). 
Further inquiry revealed that the patient’s daughter has facial fea-
tures resembling those of her father and a history of patent ductus 
arteriosus (PDA), acroosteolysis. He also gave history of abortion of a 
female fetus with cardiac developmental defect. Genetic testing was 
advised for confirmation of the disease and subsequent management. 
During his most recent follow-up visit, the patient was found to be 
doing well. He was on Prolia and was advised weight reduction, lifestyle 
measures, and exercise with stretch bands. 
3. Discussion 
HCS was first reported by Hajdu and Kautze in 1948 [7] and later by 
William D. Cheney in 1965 [9,10]. Prior to the molecular etiology of 
HCS being discovered, Brennan et al. described 10 key clinical mani-
festations of HCS including acroosteolysis, Wormian bones, Platybasia, 
premature loss of teeth, micrognathia, coarse face, coarse hair, midface 
flattening, short stature (<5%), and a positive family history [11]. He 
also proposed a diagnostic tool on the basis of a series of physiological 
parameters and genetic inheritance [11]. 
The search strategy adopted for the literature review to understand 
Table 1 
Results of bone biochemistry & DXA findings of the patient in 2019 & 2017.  
Variable 2019 2017 
Bone Biochemistry 
Serum Calcium (8.6–10.2mg/dl) 9.3 9.4 
Serum Phosphorus (2.5–4.5 mg/dl) 3.3 2.9 
Serum Magnesium (1.6–2.6 mg/dl) 1.7 2.0 
Serum 25-hydroxy vitamin D (>20ng/ml) 36.1 31.9 
Serum 1,25-hydroxy vitamin D (19.9–79.3 pg/mL) – 46.7 
Parathyroid hormone (PTH) (16–87pg/ml) 59.9 55.5 
Serum N-terminal telopeptide (NTx) (5.4–24.2 nMBCE/L) 13.93 16.69 
DXA Findings 
Left Hip BMD 0.863 0.866 
Z score − 1.0 − 1.1 
Femoral Neck (FN) BMD 0.646 0.666 
Z score − 1.7 − 1.6 
Spine BMD − 4.4 0.598 
Z score − 4.3 − 4.5 
L (distal) forearm BMD 0.617 0.649 
Z score − 3.6 − 2.9  
Fig. 1. Consort showing the Selection of Manuscripts for Review on Hajdu 
Cheney Syndrome. 
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the phenotype and genotypic variability in patients with confirmed 
NOTCH2 mutations is summarized in Fig. 1. Tables 2 and 3 shows the 
full spectrum of phenotypic and radiological manifestations reported so 
far with confirmed NOTCH2 mutations. Substantial phenotypic vari-
ability amongst patients’ results in a syndrome that often remains un-
diagnosed until adolescence or adulthood despite being congenital and 
manifesting at birth. Furthermore, the plethora of clinical symptoms 
leads to many potential differentials amongst physicians who are un-
aware of this syndrome. 
Acroosteolysis and osteoporosis are two most common radiographic 
findings followed by Wormian bones & Platybasia. Acroosteolysis usu-
ally develops after the first few years of life and progresses through 
adulthood, while severe osteoporosis occasionally occurs with fishbone 
deformity [12]. Although Acroosteolysis is a hallmark of HCS, it can also 
be secondary to a variety of other disorders. These may include auto-
immune disorders such as Scleroderma, Systemic Lupus Erythematous, 
Rheumatoid Arthritis, and Raynaud’s Disease; or neuropathies such as 
Diabetes Mellitus [13]. Other causes include trauma, burns, frostbite, 
toxic steep (due to PVC or ergot poisoning), and infections [13]. 
The multitude of presentations associated with HCS are linked to the 
NOTCH2 gene, as Notch signaling is one of the core signaling pathways 
that control embryonic development [14]. Hence, mutations in the 
Notch signaling pathway cause developmental phenotypes that affect 
various organs including the liver, skeleton, heart, eye, face, kidney, and 
vasculature. Gene sequencing has revealed a wide array of nucleotide 
mutations and protein alterations associated with HCS (Table 4). These 
differences and variability may also account for the diverse phenotypic 
spectrum as seen in literature. To the best of our knowledge, nucleotide 
mutations of c.6933delT, c.6854delA, c.6787C.T, and 
c.6424-6427delTCTG were all determined to be novel, with c.6428T > C 
being the most common mutation found in literature. The 
c.6426_6427insTT mutation our patient was found to have via gene 
sequencing too appears to be a novel mutation, which has not previously 
been reported in literature. 
At present, definitive or effective pharmacological treatment for HCS 
is not available. The hallmark of the disease, however, is acroosteolysis 
and osteoporosis and, even though the exact molecular mechanism of 
bone loss is not yet known, bisphosphonate therapy is essentially 
empirical. According to the current knowledge that the main mechanism 
of bone disease is the activation of osteoclasts, through RANK activation, 
antiresorptive rather than anabolic treatment seems to be more appro-
priate; thus, most cases reported have been administered antiresorptive 
medications. As shown by our review, bisphosphonate therapy 
(Zoledronate, Pamidronate, and Alendronate), alone or as part of a 
treatment regimen, has been consistently utilized to counteract the 
progression of osteoporosis associated with the disease. Teriparatide and 
Denosumab have also been utilized for the skeletal manifestations of the 
syndrome. From what we were able to determine in our review, these 
therapies may not offer as much therapeutic benefit as that of 
Bisphosphonates (Table 5). This difference may likely be attributed to 
the variation in dosing regimens, as well as a lack of adequate data 
rather than simply being a measure of drug efficacy. Furthermore, our 
review also found differences between the therapeutic benefit of 
different Bisphosphonates. These results may, however, also be attrib-
uted to different scan intervals, dosing regimens, and age of the patients. 
As such, it is critical that further trials are done to determine the ideal 
symptomatic therapy for this disease. 
In HCS, mutations in the terminal exon of NOTCH2 lead to the cre-
ation of a stop codon upstream of the PEST domain, responsible for 
ubiquitination and degradation of Notch, leading to a persistence of 
Table 2 
Phenotypic findings by organ systems & frequency (n) in hajdu cheney syn-
drome with NOTCH2 mutations reported in literature from 2012 to 2019.  
Systems Manifestation Frequency 
(n) 
Craniofacial Auricular Abnormalities 21 
Retro/micrognathia 20 
Coarse hair 14 








Wide nose, Cleft palate 9 
Large head circumference 5 
Prominent forehead 3 
Down turned mouth, Telecanthus 2 cases each 
Short nose, Pale skin, Small face 1 case each 
Dentition Loss of teeth 11 
Malocclusion 4 
Irregular wide-spaced teeth & Dental 
hypermobility 
2 cases each 
Short roots of permanent teeth 1 
Cardiovascular PDA 7 
Sub aortic stenosis 2 
VSD, Coarctation of the aorta, Hypoplastic left 
ventricle, Supraventricular tachycardia 
1 case each 
Eye Exophthalmos 4 
Glaucoma, Myopia 1 case each 
Pulmonary Pneumonia, Upper airway obstruction 2 cases each 
Pulmonary hypertension, Idiopathic pulmonary 
hemosiderosis 
1 case each 
Fibrosis of lungs 1 
Renal Renal cysts 6 
Polycystic kidney disease 1 
End stage renal disease 1 
Other Findings Hyploplasia of the nails, clubbed fingers, 
Cryptorchidism 
3 cases each 
GI malrotation, Polyhydramnios, Inguinal hernia 2 cases each 
Splenomegaly, Anterior crossbite, Psoriatic 
arthritis 
1 case each  
Table 3 
Radiographic Findings in Systems & their Frequency (n) in Hajdu Cheney Syn-





HEAD Wormian Bones 17 
Platybasia/Basilar Invagination 10 
Dilatation of ventricles 6 
Open skull sutures, Bathrocephaly 5 cases each 
Chiari malformation 3 
Thin corpus callosum, Paranasal sinus 
hypoplasia, Lack of frontal sinus 
2 cases each 
Scaphocephalus, Thin superior cerebellar 
peduncles, Arachnoid cyst posterior fossa with 
defect in occipital bone, Tympanic bone 
incompletely formed, Irregular 
temporomandibular joint 
1 case each 
LIMBS Acroosteolysis 23 
Fracture of long bones 7 
Brachydactyly 6 
Fibular bowing (serpentine fibulae), Hallus 
Valgus/Varus 
5 
Radial dislocation 3 
Genu Valgus/Varus, Syndactyly, Hip dysplasia, 
Clubbed foot, Low trauma fractures 
2 
Hip protrusion, Loss of normal femoral 
epiphysis, Abnormal ankle mortise, Accessory 
naviculae, Mild bowing of tibia, Planovalgus, 
Pes Valgus, Pes Planus, Lordosis, Broad valgus 
toes, Pes cavus, Cubitus valgus 
1 case each 
SPINE Osteoporosis/osteopenia 21 
Vertebral fractures 11 
Scoliosis- kyphosis 10 
Fishbone deformity 4 
Syringomyelia, Sclerosis of anterior vertebral 
endplates 
3 cases each 
Spondylolisthesis, Degenerative disk disease 1  
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NOTCH2 signaling [1,4]. Hence NOTCH2 itself could be a future target 
for management of the disease, which would counteract the underlying 
pathophysiology of the disorder as opposed to the current symptomatic 
treatment available. Experimental modalities to control Notch signaling, 
including the use of antibodies to the Notch extracellular domain or its 
ligands and the use of cell membrane-permeable peptides that interfere 
with the formation of the Notch transcriptional complex [15,16] could 
be considered as future experimental therapies for HCS. These ap-
proaches, however, may result in severe unwanted events [17]. For 
example, impaired Notch signaling has resulted in gastrointestinal 
toxicity and vascular tumors in experimental animals [17]. Therefore, 
further controlled trials are warranted to ensure the successful imple-
mentation of a regimen better suited for the management of this disease. 
Moreover, the prognosis of HCS further worsens when basilar 
invagination causes neurologic complications, or thoracic deformities 
that might lead to respiratory restriction. Due to the low prevalence and 
the lack of quality of life information available about this syndrome, it is 
difficult to assess the years of healthy host life. 
4. Conclusion 
HCS due to NOTCH2 defect is an important differential diagnosis to 
consider in cases with acroosteolysis, osteoporosis, and multiple 
craniofacial anomalies. Gene testing can facilitate in reaching the cor-
rect diagnosis. The goal of treatment is to reduce the associated symp-
toms and to prevent osteoporotic fractures. To the best of our 
knowledge, this is the first case of Hajdu Cheney Syndrome to date 
which has been diagnosed and reported from Pakistan. This is not 
necessarily indicative of a decreased prevalence, however, but instead of 
a much larger issue regarding unavailability of the diagnostic tests in the 
country, requiring out sourcing to foreign labs, adding to the cost that 
has to borne by the family. Therefore, coupled with the rarity of the 
disease itself and the vast phenotypic spectrum with which it presents, 
the disorder can remain undiagnosed for years, especially in developing 
countries, as clinical suspicion is not enough to determine diagnosis. The 
resultant delay in treatment and management can lead to an overall 
increase in morbidity. In light of this, it is imperative that proper 
treatment and management strategies are devised alongside a structured 
diagnostic criterion as well as increased availability of molecular testing 
for rare diseases in Pakistan. 
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Table 4 
Spectrum of nucleotide mutations & protein alteration in notch 2 gene in patients with hajdu cheney syndrome reported from 2010 to 2019 (N = 32).  




1 Stathopoulos, I et al. [18] 2012 Greece 1 31 F c.6450delT p.Pro2149Profs5X 
2 Lee, G et al. [19] 2013 Korea 1 21 M c.6443T > G p.Leu2148 
3 Gu, J et al. [20] 2013 China 1 57 F c.6622C > T p.Gln2208X 
4 Narumi, Y et al. [21] 2013 Japan 6 14 F c.7081C > T p.Gln2361X 
2 F c.6409G > T p.Glu2137X 
31 F c.6190_6212dup p. Pro2071AsnfsX4 
41 F c.6428T > C p.Leu2148X 
20 M c.6428T > C p.Leu2148X 
46 F c.6428T > C p.Leu2148X 
5 Descartes, M et al. [22] 2014 USA 1 47 F c.6933delT p.His2212Glnfs9 
6 Han, M et al. [23]. 2015 Korea 2 3 M c.6854delA p.Q2285Rfs2294 
32 F 
7 Deprouw, C et al. [24] 2015 France 1 36 F Q2223X C > T Not Reported 
8 Battelino, N et al. [25] 2016 Slovenia 1 8 M c.6909dup p.lle2304Hisfs9 
9 Giovani, A et al. [26] 2016 Italy 2 33 F c.6667C > T p.Gln2223Ter 
5 M 
10 Sakka, S et al. [27] 2017 England 4 15 F c.6902T.A p.Leu2301 
6 M c.6662-6663delTG p.Val2221GlufsX22 
15 M c.6787C.T p.Gln2263 
17 F c.6724_6725delAG p.Ser2242 
11 Lee, J et al. [28]. 2018 Korea 1 10 F c.6787C > T p.Gln2263 
12 Swan, L et al. [29] 2018 Australia 1 NA M c.7066G > A p.Ala2317Tr 
13 Midro, A et al. [30] 2018 Poland 1 9 M c.6424-6427delTCTG p.Ser2142ArgfsX4 
14 Pittaway J et al. [31] 2018 England 5 6 F c.7198C > T p.Arg2400X 
8 
24 
F Not Reported p.Pro2149Argfs 2×
15 This study 2020 Pakistan 1 37 M c.6426_6427insTT p.Glu2143Leufs*5  
Table 5 
Treatment response of patients with HCS to various available anti-osteoporotic 
drugs reported in literature.  












PTH Analogue 5 Teriparatide Not 
Reported 
− 4.3 − 3.0 
Monoclonal 
Antibody 
9 Denosumab Not 
Reported 
− 4.2 Not 
Reported 
Bisphosphonates 9 Zoledronic 
Acid 
5 − 4.1 − 0.7 
10 Pamidronate 2 − 3.1 − 2.6 
12 Zoledronate 3 − 3.4 − 2.4 
Pamidronate 
Alendronate 
6 − 1.9 0.1 
Zoledronate 1½ − 0.8 − 0.7 
Zoledronate 2½ − 2.1 − 1.7 
16 Pamidronate 6 − 3.1 − 1.3 
Pamidronate 
Zoledronate 
1½ − 1.7 − 0.3 
2½ − 2.9 − 2.5 
Pamidronate 3 − 4.4 − 4.5 
Alendronate 6 − 3.0 − 4.5 
Pamidronate 8½ − 3.6 − 3.0  
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